NASDAQ$SION
Sionna Therapeutics Inc · Q2 2026 earnings
Q2 2026 earnings · · Before market open
Briefing
Sionna Therapeutics Inc reported a net loss of $29.9 million for the second quarter of 2026.
The clinical-stage biopharmaceutical company focused on cystic fibrosis treatments recorded operating expenses of $32.5 million in Q2 2026, driven by increased research and development activities. Research and development expenses rose 42% year-over-year to $21.9 million while general and administrative expenses increased to $10.6 million. The company ended the quarter with $63.3 million in cash and cash equivalents and no product revenue.
- Net loss widened to $29.9 million from $18.1 million in Q2 2025 due to higher operating expenses.
- Research and development expenses increased 42% to $21.9 million, reflecting advancement of NBD1 stabilizer programs.
- General and administrative expenses rose 63% to $10.6 million, primarily from personnel and stock-based compensation growth.
- Cash and cash equivalents stood at $63.3 million with marketable securities providing additional liquidity of over $200 million.
Headline financials
Revenue & EPS history
Sionna Therapeutics Inc · Revenue · Quarterly
$0
Forward guidance
The company plans to report topline data from Phase 2a and Phase 1 combination trials in summer 2026 and continues to advance NBD1 stabilizer programs.
Tailwinds
- Strong cash position supports operations into 2028
- Advancement of clinical programs with positive Phase 1 data
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 4 quarterly earnings reports
-0.4%
Avg return
Earnings day
+2.6%
Avg return
5 days after
+15.4%
Avg return
30 days after
40%
2 / 5 earnings
Positive
+13.4%
Q2 2025
Best reaction
-11.3%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q1 2026 | -11.3% | -12.4% | -21.8% | |
| Q4 2025 | -7.2% | -1.7% | +13.0% | |
| Q3 2025 | -1.6% | +0.4% | +13.0% | |
| Q2 2025 | +13.4% | +17.8% | +32.8% | |
| Q1 2025 | +4.7% | +9.0% | +40.1% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro